US3608070A - New surgical dressing - Google Patents

New surgical dressing Download PDF

Info

Publication number
US3608070A
US3608070A US866028A US3608070DA US3608070A US 3608070 A US3608070 A US 3608070A US 866028 A US866028 A US 866028A US 3608070D A US3608070D A US 3608070DA US 3608070 A US3608070 A US 3608070A
Authority
US
United States
Prior art keywords
dressing
skin
excipient
parts
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US866028A
Other languages
English (en)
Inventor
Lucien Nouvel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US3608070A publication Critical patent/US3608070A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S602/00—Surgery: splint, brace, or bandage
    • Y10S602/904—Film-forming bandage material

Definitions

  • NEW SURGICAL DRESSING The invention concerns a new surgical dressing applicable to the skin in the form of an ointment or cream which, on drying, leaves a solid, but flexible film.
  • the dried film peels off.
  • the dried film is not sufficiently flexible.
  • the dressing is difficult to remove with water.
  • the dressing is likely to stain garments when coloring substances, such as dyestuffs or tar, are present.
  • the dressing does not allow cutaneous perspiration to take place.
  • the dressing is too occlusive and does not let skin breath.
  • the present invention solves these difficult problems and makes it possible to secure firmly over a small or large area of any part of the body a special dressing which can be readily positioned and removed.
  • a considerable advantage of the new dressing resides in that it can be positioned in an extremely short time, for example of the order of 1 minute, and that is removed simply by dissolving it in water, accompanied by very light rubbing, so that the patient does not suffer any pain (on the other hand, the dressing will remain intact even when wetted as long as it is not rubbed).
  • Another advantage of the new dressing according to the invention is the possibility which it offers for containing the desired medicament substances and the dressing permits only slow penetration of the medicament to the patient thus avoiding overall resorption.
  • this new dressing can cover the skin and retain in position thereon an appropriate medicament, or even itself contain, in dispersion or solution, one or more suitable medicament substances.
  • Other advantages include absence of staining, intimate adherence to dermatosis and the ability to permit both cutaneous perspiration and breathing of the covered skin.
  • the excipient of the new dressing may contain notably various active principles employed in dermatology, such as antibiotics and other bactericides, disinfectants, cicatrizants, cellular regeneration elements, antimycotics, anti-inflammatory agents, venotonic agents, anticoagulants, coagulants, analgesics, antiallergic diffusion products, keratolytics, revulsants, radio protectors, ichthammol, antisolar agents, antitussives, decontractants, local anaesthetics, sulphonamides, benzyl alcohol, quaternary ammonium compounds, zinc salts, enzymes, tars, coloring agents, and the like.
  • active principles employed in dermatology such as antibiotics and other bactericides, disinfectants, cicatrizants, cellular regeneration elements, antimycotics, anti-inflammatory agents, venotonic agents, anticoagulants, coagulants, analgesics, antiallergic diffusion products, keratolytics, revulsants, radio protectors, icht
  • the excipient according to the invention is very suitable for the preparation of a paste based upon a radiological protector, for example Pb powder, Pb silicate or sulfate or the like.
  • the dressing excipient according to the invention is composed essentially of vinyl pyrrolidone-vinylacetate copolymer which is soluble in a lower aqueous alcohol and which is capable of giving a film on the skin; a thixotropic agent of a triglyceride of hydropylated fatty acids having 12-24 carbon atoms, preferably l2-hydroxystearic acid glyceride; a solvent for the resin, which fairly rapidly dries on the skin, namely aqueous alcohol; and a plasticizer preferably of polyoxyethylene-glycol and/or acetoglycerides.
  • the proportions of these constituents are such that the product obtained is in the form of an ointment or a cream, depending upon the concentration.
  • the thixotropic agent may also comprise other materials known to produce thixotropic efiects, as referred to, for example, in Modern Plastics Encyclopedia, 1968, page 396.
  • Such agents may be notable mineral, organic or mixed compounds, namely siliceous minerals, more particularly based on aluminum, magnesium and/or silicon and comprising hydroxy groups; kaolin; colloidal or microcrystalline silica; clays, above all of the montmorillonite group, notably bentonite, optionally modified by organic compounds such as amines or compounds having onium groups which replace some of the cations (Na) of the bentonite; oxides; carbonates or sulfates of alkaline-earth metals; metallic stearates, more particularly those of aluminum, zinc or calcium; waxes; etc; those preferred are cationic bentonite, kaolin and/or colloidal silic, particularly in extra fine form, e.g., aerosil.
  • such other thixotropic agents may comprise up to percent of the total thixotropic material present, the remainder being the triglyceride, preferably the triglyceride of l2-hydroxystearic acid.
  • the thixotropic agent performs a very special and important function in the dressing according to the invention, since it imparts to the product the mechanical stability necessary for obtaining an ointment. Without this constituent, theproduct would form a too-fluid mixture; owing to its presence, the ointment acquires, immediately after it has been spread onto the skin, appropriate rigidity and hardness, due to the thixotropic effect of the adjuvant.
  • the thixotropic agent more particularly triglyceride of hydroxystearic acid, imparts to the film obtained the desired resistance to water and to mechanical actions.
  • the proportion of thixotropic agent in the dressing composition may vary somewhat; generally, it is from 15 to 35 parts by weight based on l00 parts by weight of the resin, and preferably it comprises l8-27 parts by weight.
  • the plasticizer has the function of preventing the film from pulling the skin and flaking.
  • plasticizer there may be employed: (l) a polyoxyalkylcne polyol (ether), such as polyoxyethylene glycol; (2) a mixed ester of polyol, i.e., a combination of a polyol (glycol, glycerine) with two different organic carboxylic acids, one of which is a fatty acid and the other a lower aliphatic acid; (3) a mixture of an ether (l) with an ester (2).
  • the mixed esters can be illustrated by the following formulas in the cases of ethylene-glycol and of glycerine taken as polyols:
  • R-CCOH is an aliphatic lower acid, such as for example acetic, propionic, butyric, etc., up to six carbon atoms
  • R'- COOl-l is a fatty acid, for instance oleic, stearic, palmitic, etc.
  • acetoglycerides that is mixed esters of glycerine as above, in which RCOO- is acetic group and R'COO- fatty acid moiety, mainly oleic.
  • a particularly advantageous plasticizer is the diacetic ester of glyceryl monoleate. These materials function very well and are harmless to the skin.
  • the proportion of plasticizer may be from 20 to 40 parts per 100 parts resin and preferably from 25 to 30 parts based on the weight of the resin.
  • the solvent most commonly employed in pharmacy being ethyl alcohol, it is ethanol (95) [95 percent by volume] which constitutes the most suitable solvent for the excipient according to the invention.
  • the total quantity of solvent is generally of the same order, i.e., about 60 to 120 parts per 100 parts resin, as that of the resin. However, the preferred quantity is 7080 parts solvent per 100 parts resin.
  • the specific resin for use according to the invention is a copolymer of vinylpyrrolidone and vinyl acetate, containing by weight 20 to 80 percent of vinylpyrrolidone and 80 to 20 percent of vinylacetate. Best copolymers are those which contain 30 to 70 percent of vinylpyrrolidone with 70 to 30 percent vinylacetate. It has been found that particularly suitable excipient is obtained when one mixes a copolymer rich in vinylpyrrolidone (e.g., 60 to 70 percent vinylpyrrolidone) with a copolymer poor in vinylpyrrolidone (for instance having 30 to 40 percent of vinylpyrrolidone).
  • a preferred dressing contains a mixture of copolymers, such that in 100 parts of the mixture there are:
  • the new excipient is prepared by very intimately mixing the four kinds or more of the above-indicated compounds. It is to be noted that the finer the dispersion of the triglyceride of 12- hydroxystearic acid (with or without added bentonite) in the product formed, the more the latter imparts a favorable thixotropy to the formation of the dressing on the skin. As indicated above, various medicament substances may be incorporated in the excipient; this incorporation may take place during the preparation, or after the latter, by mixing the medicaments with the ointment already formed.
  • EXAMPLE 1 Preparation of an excipient according to the invention. The weights are in grams.
  • PVPE vinyl polyvinylpyrrolidone acetate
  • PVIAV vinyl polyvinylpyrrolidone acetate
  • egg yolk alcohclate 15%) in the course of the manufacture, it is necessary to add a certain quantity of 95 ethyl alcohol in order to counteract the losses 1% the evaporation of the solvent.
  • 2% 630 and the triglycerides of l2-hydroxystearic acid are first introduced. The two powders are first well mixed by stirring and the acetoglyceride LC and the egg yolk alcoholate are added.
  • the mixture is stirred until a paste is obtained, whereafter the aerosil (colloidal silica) is added in proportions of 4 percent to 7 percent, and then the water.
  • the mixture is stirred until all the lumps have disappeared.
  • the polyoxyethylene glycol (Carbowax) is added and then the alcohol, if necessary, and finally the PVP/VA 335.
  • EXAMPLE 2 Formula (21) In 100 parts by weight of excipient prepared in accordance with example l is incorporated the following mixture:
  • Biclotymol i.e., 2,2-methylene-bis (4- chlorothymol) 0.2 part of parachlorphenoxytol 0.2 part of vitamin A acetate 100,000 IU/g
  • lignocain hydrochloride 6.0 parts of ethyl alcohol 0.12 part of 2.5 percent eosin solution.
  • Formula (b) For an ointment for use by sportsmen.
  • Glycerol ether of ortho-creso1 10 g. Methyl nicotate I g. Escin (anti-inflammatory substance emanating from horsechestnut) 1 g. Glycol salicylate 5 g. Excipient q.s.7o
  • Formula (c) A product for application to the chest for coughing.
  • Example 4 0.10 to 1 g. of Biclotymol 0. 10 to 1 g. of triamcinolone acetonide (Example 5) 0.10 to l g. of neomycin sulfate (expressed as base) (Example 6) 5 to 20 g. of undecylenic acid (Example 7) 5 to 10 g. of flavonoids (Example 8) 1 to 5 g.
  • An excipient according to claim 1 wherein said thixotropic agent also comprises up to percent thereof of a siliceous mineral material chosen from the group consisting of bentonite, colloidal silica and kaolin.
  • An excipient according to claim 1 wherein said thixotropic agent is the triglyceride of l2-hydroxystearic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US866028A 1969-06-10 1969-10-13 New surgical dressing Expired - Lifetime US3608070A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR6919036A FR2047874A6 (pt) 1969-06-10 1969-06-10

Publications (1)

Publication Number Publication Date
US3608070A true US3608070A (en) 1971-09-21

Family

ID=9035419

Family Applications (1)

Application Number Title Priority Date Filing Date
US866028A Expired - Lifetime US3608070A (en) 1969-06-10 1969-10-13 New surgical dressing

Country Status (8)

Country Link
US (1) US3608070A (pt)
BE (1) BE734506A (pt)
CA (1) CA945070A (pt)
CH (1) CH519341A (pt)
DE (1) DE1931080B2 (pt)
FR (1) FR2047874A6 (pt)
GB (1) GB1279294A (pt)
NL (1) NL6909365A (pt)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880158A (en) * 1974-04-04 1975-04-29 Johnson & Johnson Spray-spun bandage composition
US4210633A (en) * 1978-10-20 1980-07-01 Eli Lilly And Company Flurandrenolide film formulation
US4289749A (en) * 1979-08-14 1981-09-15 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylpropanolamine
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
WO1982000099A1 (en) * 1980-07-09 1982-01-21 Key Pharma Polymeric diffusion matrix for administration of drugs
EP0107277A1 (en) * 1982-09-30 1984-05-02 Gaf Corporation Pliable films of polymeric halogen complexes
US4479933A (en) * 1980-02-14 1984-10-30 Vsesojuzny Nauchnoissledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki Composition for sealing wound surfaces
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4482534A (en) * 1980-12-16 1984-11-13 Forest Laboratories, Inc. Nitroglycerin preparations
US4584192A (en) * 1984-06-04 1986-04-22 Minnesota Mining & Manufacturing Company Film-forming composition containing an antimicrobial agent and methods of use
US5128138A (en) * 1989-07-21 1992-07-07 Izhak Blank Estradiol compositions and methods for topical application
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
US5320838A (en) * 1992-12-21 1994-06-14 Pro Cure Products, Ltd. Protectant for irritated skin containing polyethyleneglycols, polyvinylether salt anhydride and polyvinylpyrrolidone
WO1994022504A1 (de) * 1993-04-05 1994-10-13 Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh Filmbildende wundgele mit desinfizierender wirkung
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5558872A (en) * 1995-03-07 1996-09-24 Healthpoint Medical Limited Partnership Gelled mineral oil skin protectant
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US5658559A (en) * 1992-12-16 1997-08-19 Creative Products Resource Associates, Ltd. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
EP0888141A1 (en) * 1996-03-12 1999-01-07 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
US6479076B2 (en) 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
US6716463B1 (en) * 1997-12-03 2004-04-06 Nippon Suisan Kaisha, Ltd Coating agent for cooking range heated frozen food comprising core food and layer of coating, and food using the same
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
WO2007132239A2 (en) * 2006-05-17 2007-11-22 Aston University Adhesive solution for application to the skin
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US20080085972A1 (en) * 2006-10-05 2008-04-10 O'brien Emmett Patrick Switchable adhesive article for attachment to skin and method of using the same
US20170283622A1 (en) * 2015-04-21 2017-10-05 Behr Process Corporation Decorative coating compositions
US9821084B2 (en) 2005-02-15 2017-11-21 Virginia Commonwealth University Hemostasis of wound having high pressure blood flow using kaolin and bentonite
US9867898B2 (en) 2006-05-26 2018-01-16 Z-Medica, Llc Clay-based hemostatic agents
US9889154B2 (en) 2010-09-22 2018-02-13 Z-Medica, Llc Hemostatic compositions, devices, and methods
US10314935B2 (en) 2009-01-07 2019-06-11 Entrotech Life Sciences, Inc. Chlorhexidine-containing antimicrobial laminates
US10960100B2 (en) 2012-06-22 2021-03-30 Z-Medica, Llc Hemostatic devices
US11039615B2 (en) 2014-04-18 2021-06-22 Entrotech Life Sciences, Inc. Methods of processing chlorhexidine-containing polymerizable compositions and antimicrobial articles formed thereby

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1028621A (en) * 1972-05-19 1978-03-28 Kent J. Valan Powder melts and emulsions of a poly (n-vinyl lactam) and an unsaturated fatty acid component
DE2432925C3 (de) * 1974-07-05 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen Folienförmige Arzneimittel
DE2514099A1 (de) * 1975-03-29 1976-10-14 Henkel & Cie Gmbh Kosmetische emulsionen vom wasser- in-oel-typ und deren herstellung
DE2514100A1 (de) * 1975-03-29 1976-10-07 Henkel & Cie Gmbh Kosmetische emulsionen vom wasser- in-oel-typ und deren herstellung
LU78831A1 (fr) * 1978-01-06 1979-09-06 Oreal Composition pour le nettoyage de la peau
FR2463617A1 (fr) * 1979-08-20 1981-02-27 Thorel Jean Noel Nouvelles compositions amincissantes a base de mucopolysaccharides et d'escine
LU83710A1 (fr) * 1981-10-23 1983-06-07 Cird Matrice de diffusion polymerique a base d'anthraline ou de l'un de ses derives et son application dans le traitement des maladies de la peau
EP0124665B1 (en) * 1983-05-05 1988-04-20 Quinoderm Limited Dermatological compositions
FR2566270A1 (fr) * 1984-06-25 1985-12-27 Ausonia Farma Srl Formes pharmaceutiques sous forme de gel, pour l'application topique de principes actifs
DE3438005A1 (de) * 1984-10-17 1986-04-17 Röhm GmbH, 6100 Darmstadt Pharmazeutisches mittel zur lokalen therapie der psoriasis
DE3612305A1 (de) * 1986-04-11 1987-10-22 Roehm Pharma Gmbh Fluessige arzneiform zur therapie der psoriasis auf basis filmbildender polymere
EP0289900A1 (en) * 1987-04-30 1988-11-09 Abbott Laboratories Topical antibacterial compositions
US5082656A (en) * 1987-04-30 1992-01-21 Abbott Laboratories Topical antibacterial compositions containing penetration enchancers
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
FR2642976B1 (fr) * 1989-02-15 1997-11-14 Ramond Gerard Voile conducteur cutane pour l'application de courants a un sujet dans un but therapeutique ou esthetique, et appareillage utilisant un tel voile
DE4006628A1 (de) * 1990-03-06 1990-11-22 Bernd Dr Med Ditter Verfahren zur oertlichen daueranwendung von antiallergischen, entzuendungshemmenden und juckreizstillenden hautmitteln
DE19833177A1 (de) * 1998-07-23 2000-01-27 Labtec Gmbh Pflasterabdeckung nach Reizung
FR2799369B1 (fr) 1999-10-08 2001-12-21 Oreal Association d'escine et de sulfate de dextran et son utilisation
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
CN107233607B (zh) * 2017-06-27 2020-03-31 东莞御治医疗器械有限公司 一种创面保护膜材料的制备方法

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880158A (en) * 1974-04-04 1975-04-29 Johnson & Johnson Spray-spun bandage composition
US4210633A (en) * 1978-10-20 1980-07-01 Eli Lilly And Company Flurandrenolide film formulation
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4470962A (en) * 1979-08-14 1984-09-11 Key Pharmaceuticals, Inc. Polymeric diffusion matrix
US4292302A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing terbutaline
US4292303A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing clonidine
US4292301A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing ephedrine
US4294820A (en) * 1979-08-14 1981-10-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylephrine
US4321252A (en) * 1979-08-14 1982-03-23 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing ester derivatives of estradiol
US4492685A (en) * 1979-08-14 1985-01-08 Key Pharmaceuticals, Inc. Protective skin matrix
US4289749A (en) * 1979-08-14 1981-09-15 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylpropanolamine
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4479933A (en) * 1980-02-14 1984-10-30 Vsesojuzny Nauchnoissledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki Composition for sealing wound surfaces
WO1982000099A1 (en) * 1980-07-09 1982-01-21 Key Pharma Polymeric diffusion matrix for administration of drugs
US4482534A (en) * 1980-12-16 1984-11-13 Forest Laboratories, Inc. Nitroglycerin preparations
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
EP0107277A1 (en) * 1982-09-30 1984-05-02 Gaf Corporation Pliable films of polymeric halogen complexes
US4584192A (en) * 1984-06-04 1986-04-22 Minnesota Mining & Manufacturing Company Film-forming composition containing an antimicrobial agent and methods of use
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5128138A (en) * 1989-07-21 1992-07-07 Izhak Blank Estradiol compositions and methods for topical application
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
US5658559A (en) * 1992-12-16 1997-08-19 Creative Products Resource Associates, Ltd. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US5320838A (en) * 1992-12-21 1994-06-14 Pro Cure Products, Ltd. Protectant for irritated skin containing polyethyleneglycols, polyvinylether salt anhydride and polyvinylpyrrolidone
WO1994022504A1 (de) * 1993-04-05 1994-10-13 Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh Filmbildende wundgele mit desinfizierender wirkung
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US5558872A (en) * 1995-03-07 1996-09-24 Healthpoint Medical Limited Partnership Gelled mineral oil skin protectant
EP0888141A1 (en) * 1996-03-12 1999-01-07 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
EP0888141A4 (en) * 1996-03-12 2001-01-17 Adolor Corp FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD FOR TREATING HYPERALGESIA
US6716463B1 (en) * 1997-12-03 2004-04-06 Nippon Suisan Kaisha, Ltd Coating agent for cooking range heated frozen food comprising core food and layer of coating, and food using the same
US6479076B2 (en) 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
US9821084B2 (en) 2005-02-15 2017-11-21 Virginia Commonwealth University Hemostasis of wound having high pressure blood flow using kaolin and bentonite
US11167058B2 (en) 2005-02-15 2021-11-09 Virginia Commonwealth University Hemostasis of wound having high pressure blood flow
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
WO2007132239A2 (en) * 2006-05-17 2007-11-22 Aston University Adhesive solution for application to the skin
WO2007132239A3 (en) * 2006-05-17 2008-05-15 Univ Aston Adhesive solution for application to the skin
US20090209685A1 (en) * 2006-05-17 2009-08-20 Alan Amass Adhesive Solution for Application to the Skin
US10960101B2 (en) 2006-05-26 2021-03-30 Z-Medica, Llc Clay-based hemostatic agents
US9867898B2 (en) 2006-05-26 2018-01-16 Z-Medica, Llc Clay-based hemostatic agents
US10086106B2 (en) 2006-05-26 2018-10-02 Z-Medica, Llc Clay-based hemostatic agents
US11123451B2 (en) 2006-05-26 2021-09-21 Z-Medica, Llc Hemostatic devices
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US20080085972A1 (en) * 2006-10-05 2008-04-10 O'brien Emmett Patrick Switchable adhesive article for attachment to skin and method of using the same
US7879942B2 (en) 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same
US10314935B2 (en) 2009-01-07 2019-06-11 Entrotech Life Sciences, Inc. Chlorhexidine-containing antimicrobial laminates
US9889154B2 (en) 2010-09-22 2018-02-13 Z-Medica, Llc Hemostatic compositions, devices, and methods
US11007218B2 (en) 2010-09-22 2021-05-18 Z-Medica, Llc Hemostatic compositions, devices, and methods
US10960100B2 (en) 2012-06-22 2021-03-30 Z-Medica, Llc Hemostatic devices
US11559601B2 (en) 2012-06-22 2023-01-24 Teleflex Life Sciences Limited Hemostatic devices
US11039615B2 (en) 2014-04-18 2021-06-22 Entrotech Life Sciences, Inc. Methods of processing chlorhexidine-containing polymerizable compositions and antimicrobial articles formed thereby
US10118864B2 (en) * 2015-04-21 2018-11-06 Behr Process Corporation Decorative coating compositions
US20170283622A1 (en) * 2015-04-21 2017-10-05 Behr Process Corporation Decorative coating compositions

Also Published As

Publication number Publication date
DE1931080C3 (pt) 1978-12-21
CA945070A (en) 1974-04-09
BE734506A (pt) 1969-12-15
FR2047874A6 (pt) 1971-03-19
NL6909365A (pt) 1970-12-22
GB1279294A (en) 1972-06-28
DE1931080B2 (de) 1978-04-20
DE1931080A1 (de) 1970-12-23
CH519341A (fr) 1972-02-29

Similar Documents

Publication Publication Date Title
US3608070A (en) New surgical dressing
DE69535737T2 (de) Pflaster zur externen anwendung
ES2829386T3 (es) Parche de administración transdérmica
KR100449939B1 (ko) 트라니라스트함유외용제제및그제조방법
US20030027833A1 (en) Compositions and delivery systems for administration of a local anesthetic agent
DE3131610A1 (de) "auflage mit einem gehalt an mikroverkapseltem nitroglyzerin, die zur perkutanten verabreichung von nitroglyzerin geeignet ist"
DE3710293A1 (de) Wasserfeste sonnenschutz-zusammensetzung
SI9012260B (sl) Postopek za izdelavo transdermalnih terapevtskih sistemov z buprenorfinom kot dejavno sestavino
JPH07258060A (ja) 皮膚美白用貼付剤
NZ209843A (en) Transdermal delivery system for administration of nitroglycerin
JP2008308453A (ja) ゲル組成物およびその用途
JP2004524421A (ja) 局所施用向け被膜形成組成物及び活性作用物質の送達のためのその利用
KR101440318B1 (ko) 피부용 패치 조성물 및 이를 이용한 피부용 패치의 제조방법
SE9202066L (sv) Prokaterol-haltigt preparat foer paafoering paa huden
SK114199A3 (en) Nimesulide gel systems for topical use
EP0514794A1 (en) Plaster preparation
KR100708060B1 (ko) 오일 및 계면활성제를 함유하는 피부각전 제거용 화장료조성물
JP5319950B2 (ja) 塩酸ブテナフィン含有水性貼付剤
DE10138457B4 (de) Hygieneartikel zum Desinfizieren
JPS6034923B2 (ja) スポンジ状医薬用バンド
JPS60163811A (ja) プロプラノロ−ル含有外用貼付剤
KR19980076273A (ko) 경피흡수용 필름형성 겔 조성물
JPH0555485B2 (pt)
KR100353428B1 (ko) 첩부제용 가소제 및 이 가소제를 함유하는 첩부제
JPS5854956A (ja) 無水系貼付製剤